COMPANY

Lineage Cell Therapeutics

HQ: Carlsbad, CA source · lineagecell.com ↗ · West Coast

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Lineage Cell Therapeutics develops, manufactures and tests specialized human cells using its AlloSCOPE cell engineering platform. From company website Source · checked 2026-10-19

Sources for this description (1)

Lineage Cell Therapeutics develops, manufactures and tests specialized human cells using its AlloSCOPE cell engineering platform.
- “Lineage’s programs are based on its proprietary cell-based technology platform, AlloSCOPE ™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities.” https://lineagecell.com/company/ (2026-10-19)
- “From this proprietary AlloSCOPE platform, Lineage develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body.” https://lineagecell.com/company/ (2026-10-19)

Therapeutic area: degenerative disease

Keywords: Spinal Cord Injury Spinal Cord Injuries Spinal Cord Injury Cervical Spinal Cord Injury Thoracic Acute Spinal Cord Injury Chronic Spinal Cord Injury Cervical Spinal Cord Injury Spine Injury Spinal Cord Trauma OPC1 AST-OPC1 GRNOPC1

$102.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

Jun 30, 2025 Trial start Phase 1: A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury source ↗
Jan 27, 2025 Raise Follow-on offering — Registered direct: $36M (total, as published), announced Jan 27, 2025. Source: SEC filing. source ↗
Nov 20, 2024 Raise Follow-on offering — Registered direct: $66M (up to, as announced), announced Nov 20, 2024. Source: SEC filing. source ↗
Jun 13, 2018 Trial start —: LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 source ↗
2015-03 Trial start Phase 1/Phase 2: Dose Escalation Study of AST-OPC1 in Spinal Cord Injury source ↗
Oct 6, 2011 Trial start —: LTFU Study of Subjects Who Received GRNOPC1 source ↗
2010-10 Trial start Phase 1: Safety Study of GRNOPC1 in Spinal Cord Injury source ↗

Upcoming milestones

Dec 12, 2026 (ESTIMATED) · · LTFU Study of Subjects Who Received GRNOPC1 · NCT05919563
Aug 10, 2027 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury · NCT06841770
Jan 14, 2033 (ESTIMATED) · · LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 · NCT05975424

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $102.0M. Last 2 years.

Jan 27, 2025 Follow-on offering — Registered direct: $36M (total, as published), announced Jan 27, 2025. Source: SEC filing. source ↗
Nov 20, 2024 Follow-on offering — Registered direct: $66M (up to, as announced), announced Nov 20, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06841770	A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury	Phase 1	Recruiting	Jun 30, 2025	Aug 10, 2027 (estimated)
NCT05919563	LTFU Study of Subjects Who Received GRNOPC1	Not listed	Active, not recruiting	Oct 6, 2011	Dec 12, 2026 (estimated)
NCT05975424	LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1	Not listed	Active, not recruiting	Jun 13, 2018	Jan 14, 2033 (estimated)
NCT02302157	Dose Escalation Study of AST-OPC1 in Spinal Cord Injury	Phase 1/Phase 2	Completed	2015-03	2018-12 (actual)
NCT01217008	Safety Study of GRNOPC1 in Spinal Cord Injury	Phase 1	Completed	2010-10	2013-07 (actual)